Pherecydes Pharma SA
PAR:ALPHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pherecydes Pharma SA
PAR:ALPHE
|
FR |
|
L
|
Landi Renzo SpA
XMUN:ARQ
|
IT |
|
C
|
Clearday Inc
OTC:CLRD
|
US |
|
O
|
Ottakringer Getraenke AG
VSE:OTS
|
AT |
|
A
|
Avaron Mining Corp
XTSX:AVR
|
CA |
|
Mayville Engineering Company Inc
F:2YN
|
US |
|
Il Sole 24 Ore SpA
F:4IL1
|
IT |
|
Advanced Container Technologies Inc
OTC:ACTX
|
US |
|
B
|
BC Bud Corp
CNSX:BCBC
|
CA |
|
NXT Energy Solutions Inc
TSX:SFD
|
CA |
|
Neobo Fastigheter AB (publ)
F:4M2B
|
SE |
|
U
|
Ultra Brands Ltd
CNSX:ULTA
|
CA |
|
O
|
OOOOO Entertainment Commerce Ltd
XTSX:OOOO
|
CA |
|
Satellos Bioscience Inc
NASDAQ:MSLE
|
CA |
Pherecydes Pharma SA
Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. The company is headquartered in Nantes, Pays De La Loire and currently employs 27 full-time employees. The company went IPO on 2021-02-05. The firm is specialized in the research and development of anti-infective therapies based on bacteriophages. The company deploys Phagotherapy, which is a method to treat bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells. The firm focuses on the selection, characterization, and production of therapeutic bacteriophages to combat antibiotic resistance through the selection of lytic phages. The company produces therapeutic bacteriophages mainly to fight against the bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. The company is headquartered in Nantes, Pays De La Loire and currently employs 27 full-time employees. The company went IPO on 2021-02-05. The firm is specialized in the research and development of anti-infective therapies based on bacteriophages. The company deploys Phagotherapy, which is a method to treat bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells. The firm focuses on the selection, characterization, and production of therapeutic bacteriophages to combat antibiotic resistance through the selection of lytic phages. The company produces therapeutic bacteriophages mainly to fight against the bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
